Vitiligo is a chronic skin condition in which the immune system destroys the cells that produce pigment, leaving smooth white patches on the skin. It affects roughly 0.1% to 1.2% of the population worldwide, depending on the region, and can appear at any age, though it most commonly starts between the teens and early thirties. Women are affected slightly more often than men.
What Happens Inside the Skin
Your skin gets its color from cells called melanocytes, which produce a pigment called melanin. In vitiligo, those melanocytes come under attack from your own immune system through a chain of events that starts with stress inside the cells themselves.
The process begins when melanocytes experience a buildup of harmful molecules called reactive oxygen species. This chemical stress damages the cell’s internal structures and forces the melanocyte to release distress signals into the surrounding tissue. Those signals act like a flare, attracting immune cells to the area. The immune system then misidentifies melanocytes as threats. A specific type of immune cell, called a CD8+ T cell, delivers the final blow, killing melanocytes through targeted chemical attacks. Once those melanocytes are gone, the skin in that area can no longer produce pigment, and a white patch forms.
What makes vitiligo particularly persistent is that some of these immune cells take up permanent residence in the skin as “memory” cells. They remain on patrol in areas that have already lost pigment, ready to attack any melanocytes that try to return. This is one reason vitiligo can be difficult to reverse and why repigmentation sometimes fades again after treatment stops.
Types of Vitiligo
Vitiligo comes in two main forms that behave quite differently.
Non-segmental vitiligo is by far the more common type. It produces patches on both sides of the body in a roughly symmetrical pattern. The face, hands, wrists, armpits, and groin are frequently affected. It tends to expand gradually over time, both in the size of existing patches and the appearance of new ones. Hair in affected areas usually keeps its color early on, though it may turn white as the condition progresses.
Segmental vitiligo behaves differently. It appears on just one side of the body, typically stays within a defined zone, and spreads rapidly at first before stabilizing. Most of the spreading happens within six to 24 months, and further extension after that is rare. Up to 50% of people with segmental vitiligo develop white hair in the affected area early in the course of the disease. This type also tends to appear at a younger age than non-segmental vitiligo.
Causes and Triggers
Vitiligo results from a combination of genetic susceptibility and environmental triggers. Variations in more than 30 genes have been linked to increased risk, many of them involved in immune regulation. Having a close family member with vitiligo or another autoimmune condition raises your likelihood of developing it.
But genes alone don’t cause vitiligo. Something in the environment typically sets it off. Known triggers include physical trauma to the skin (cuts, scrapes, friction, sunburn), psychological stress, exposure to certain industrial chemicals, and contact with skin-lightening products. Patches frequently appear in areas prone to rubbing or impact, like the hands, elbows, and knees, or places where bones sit close to the skin surface.
How Vitiligo Is Diagnosed
Dermatologists can usually diagnose vitiligo through a visual examination alone. The hallmark is smooth, well-defined white patches, often in characteristic locations: around the eyes and mouth, on the fingertips, or around the genitals. A Wood’s lamp, which emits ultraviolet light, can help confirm the diagnosis by making depigmented areas glow more brightly, which is especially useful in people with fair skin where patches might not be obvious under normal lighting. Skin biopsies are rarely needed but may be ordered if the diagnosis is uncertain.
Linked Autoimmune Conditions
Because vitiligo stems from immune dysfunction, people with the condition are more likely to develop other autoimmune diseases. Thyroid disorders, particularly Hashimoto’s thyroiditis and Graves’ disease, are the most common. Other associated conditions include type 1 diabetes, pernicious anemia, alopecia areata, rheumatoid arthritis, and lupus. Many dermatologists will screen for thyroid problems at the time of a vitiligo diagnosis and periodically afterward.
Treatment Options
Topical Medications
Topical corticosteroids remain a first-line treatment, particularly for small or new patches. They work by calming the local immune response, giving melanocytes a chance to recover. For sensitive areas like the face and eyelids, doctors often prefer calcineurin inhibitors, which suppress immunity without the skin-thinning side effects of steroids.
A newer option is topical ruxolitinib, which became the first FDA-approved treatment specifically for vitiligo. It works by blocking the signaling pathway that recruits immune cells to attack melanocytes. In clinical studies, about 50% of patients using ruxolitinib on facial patches achieved at least 50% repigmentation. Results on the body were more modest, with roughly 30% reaching that threshold. The face and neck tend to respond best to nearly all vitiligo treatments because those areas have a denser supply of melanocyte stem cells in hair follicles.
Phototherapy
Narrowband UVB phototherapy is one of the most effective and widely used treatments for vitiligo that covers larger areas of the body. Sessions expose the skin to a specific wavelength of ultraviolet light that stimulates melanocyte stem cells to migrate from hair follicles into the surrounding skin. Treatment typically starts at a low dose and increases gradually until faint pinkness or tiny dots of pigment appear around hair follicles.
In targeted UVB studies, about 63% of treated patches achieved 75% or greater repigmentation, with another 24% reaching between 50% and 74%. Pigment typically starts returning after four to five sessions. Treatment is given once or twice a week, with both schedules producing similar results. A full course can run up to 30 sessions or more, depending on how the skin responds. Combining phototherapy with topical treatments often improves outcomes beyond what either approach achieves alone.
Surgical Options
For stable vitiligo that hasn’t responded to other treatments, surgical approaches can transplant healthy melanocytes from unaffected skin into depigmented areas. These procedures work best for segmental vitiligo, which tends to stay stable after its initial rapid phase.
Does Vitiligo Ever Reverse on Its Own?
Spontaneous repigmentation does happen, but it’s uncommon. In one study of 167 patients, about 21% experienced some degree of natural color return, but only 3.6% saw complete repigmentation. The odds improve with time: patients whose vitiligo had been stable for more than three years were 3.5 times more likely to see spontaneous repigmentation than those with shorter disease duration. When it does occur, pigment usually returns in a speckled, perifollicular pattern (tiny dots around hair follicles that gradually expand and merge).
Emotional and Social Effects
Vitiligo is medically benign, but its psychological impact can be significant. In one study of 100 patients, 95% reported that vitiligo affected their quality of life, with 38% describing the impact as “very large.” Fifty-nine percent met criteria for depression, and 8% reported suicidal thoughts. Sleep problems were reported by 89% of patients, compared to 38% of matched controls without the condition.
The emotional burden isn’t evenly distributed. Women reported significantly higher quality-of-life impacts than men. People with patches on visible areas like the face and hands scored worse on both depression and quality-of-life measures than those with patches in concealable locations. Widespread vitiligo carried the highest psychological toll. These findings reinforce that vitiligo treatment is not cosmetic in any trivial sense. Addressing the visible symptoms can meaningfully improve mental health and daily functioning.